About PharmAthene
PharmAthene is a company based in Annapolis (United States) founded in 2001. PharmAthene has raised $50 million across 3 funding rounds. The company has 15 employees as of December 31, 2016. PharmAthene has completed 1 acquisition, including Altimmune. PharmAthene operates in a competitive market with competitors including HOOKIPA Pharma, Insmed, Stallergenes Greer, Valneva and Affinivax, among others.
- Headquarter Annapolis, United States
- Employees 15 as on 31 Dec, 2016
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Pharmathene Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$50 M (USD)
in 3 rounds
-
Latest Funding Round
$9.9 M (USD), Post-IPO
Nov 18, 2010
-
Investors
Not available
-
Employee Count
15
as on Dec 31, 2016
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of PharmAthene
PharmAthene has successfully raised a total of $50M across 3 strategic funding rounds. The most recent funding activity was a Post-IPO round of $9.9 million completed in November 2010. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investments & Acquisitions by PharmAthene
PharmAthene has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Altimmune.
Investment portfolio details for PharmAthene
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Vaccines for infectious diseases and solid tumors are developed.
|
Locked | Locked | 1997 | Locked |
Complete acquisition details for PharmAthene
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - PharmAthene
Detailed financials for PharmAthene
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Pharmathene Comparisons
Peer comparison for PharmAthene
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of PharmAthene
PharmAthene operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as HOOKIPA Pharma, Insmed, Stallergenes Greer, Valneva and Affinivax, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of immunotherapies for the treatment of infectious diseases and cancer
|
|
| Locked | Locked | Locked |
Developer of small molecule inhibitors for rare lung diseases
|
|
| Locked | Locked | Locked |
Allergen immunotherapies for respiratory allergies are developed.
|
|
| Locked | Locked | Locked |
Prophylactic vaccines for infectious diseases are developed and advanced.
|
|
| Locked | Locked | Locked |
Technology-based conjugate vaccines against infectious diseases are developed.
|
|
| Locked | Locked | Locked |
In vivo gene editing technology is developed for microbiome modulation.
|
Detailed competitors of PharmAthene
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Pharmathene
Complete news archive for PharmAthene
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about PharmAthene
PharmAthene was founded in 2001 and raised its 1st funding round 3 years after it was founded.
PharmAthene is headquartered in Annapolis, United States. It is registered at Annapolis, Maryland, United States.
Vipin K Garg is the current CEO of PharmAthene.
PharmAthene is a funded company, having raised a total of $50M across 3 funding rounds to date.
As of Dec 31, 2016, the latest employee count at PharmAthene is 15.
PharmAthene is a biopharma company that focuses on defensive countermeasures against biological and chemical warfare. The company is in beginning animal studies on its next generation anthrax vaccine based on its proprietary vaccine development platform, and hopes to file for FDA approvals for human trials in 2017. Additionally, the company has also entered into an agreement with ImmunoVaccine Technologies for the exclusive use of its DepoVaxTM vaccine platform to develop an anthrax vaccine utilizing its Recombinant Protective Antigen system.
PharmAthene's top competitors include HOOKIPA Pharma, Stallergenes Greer and Valneva.
PharmAthene has made 1 acquisition, including Altimmune.